-
2023-503480-42-00
10
Hospital-acquired pneumonia
-
2024-517769-17-00
4
Poor prognosis cervico-facial lymphatic malformations (Lymphangima)
-
2024-518139-12-00
4
locally advanced or metastatic Pancreatic ductal adenocarcinoma
-
2025-523443-35-00
5
Persistent Corneal Epithelial Defect (PCED)
-
2025-523404-74-00
4
2026-05-26
Prurigo Nodularis
-
2023-503697-21-01
5
2024-06-24
Idiopathic pulmonary fibrosis
-
2023-503904-10-00
5
2024-06-07
Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
-
2023-508153-12-00
5
2024-03-26
Hospital-acquired pneumonia
-
2024-512483-59-00
5
2023-06-09
Improvement of cardiovascular outcomes in patients with advanced
chron
-
2022-501687-18-00
4
2020-10-28
Advanced malignancies and IAI diseases
-
2023-504957-11-00
5
2026-03-24
Metastatic castration resistant prostate cancer
-
2025-520730-28-00
4
2025-12-08
Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung
-
2025-521511-40-00
10
2025-11-18
metastatic non-small cell lung cancer
-
2023-509630-19-00
5
2025-07-31
Esophageal Squamous Cell Carcinoma (ESCC)
-
2024-513682-40-01
5
2025-07-04
Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer
-
2023-508132-65-00
4
2025-06-30
NEUROENDOCRINE CELLS HYPERPLASIA OF INFANCY
-
2024-516243-81-00
5
2025-06-23
myelin oligodendrocytes glycoprotein antibody associated diseases
(MOG
-
2023-509788-25-00
6
2025-06-16
Rheumatoid arthritis
-
2022-502184-38-00
4
2025-06-06
Rapidly progressive glomerulonephritis
-
2023-507666-32-00
4
2025-05-27
Inclusion body Myositis
-
2024-510893-25-00
5
2025-04-29
Brain metastases of cancer > brain radionecrosis
-
2023-505291-30-01
4
2025-03-06
Triple Negative Breast Cancer with residual disease after neoadjuvant
-
2024-511442-39-00
5
2025-02-05
Rheumatoid arthritis (RA)
-
2023-504022-19-01
5
2024-12-13
Polymyositis or dermatomyositis according to 2017 EULAR / ACR classifi